Can Tirzepatide Push Blood Sugar Back to Normal in Type 2 Diabetes? | Research

The takeaway

Tirzepatide increased the odds of achieving normal blood sugar levels (HbA1c below 5.7%) by more than 16 times compared to control treatments.

>16x odds of normoglycemia
Tirzepatide made normal blood sugar levels dramatically more achievable compared to control treatments

What the researchers found

Tirzepatide did not just improve blood sugar control. It pushed many patients with type 2 diabetes all the way to normoglycemia, meaning their HbA1c dropped below 5.7%, the threshold where diabetes is no longer diagnosed.

The odds of achieving this were more than 16 times higher with tirzepatide versus control. This raises the question of whether tirzepatide could enable drug-induced diabetes remission, where blood sugar stays normal even after stopping medication.

Why it matters

Most diabetes drugs aim to lower HbA1c to below 7%. Reaching below 5.7% is a different target entirely. It means the patient's blood sugar looks like someone without diabetes. If tirzepatide can reliably produce normoglycemia, it reframes the treatment goal from management to potential remission.

The numbers in context

- Odds ratio >16 for achieving normoglycemia (HbA1c <5.7%) with tirzepatide vs control

- Normoglycemia threshold: HbA1c <5.7%

How the study worked

The researchers analyzed data from tirzepatide clinical trials in type 2 diabetes. They specifically measured the proportion of patients achieving HbA1c below 5.7% (normoglycemia) on tirzepatide versus control groups. Odds ratios were calculated to quantify the difference.

Who was studied

Adults with type 2 diabetes in tirzepatide clinical trials

What this study cannot tell us

The abstract is brief and does not detail which trials were analyzed, the total sample size, or how long patients maintained normoglycemia. The key question of whether normoglycemia persists after stopping tirzepatide is not addressed. Achieving a lab value below 5.7% during active treatment is not the same as true disease remission.

How to read the evidence

Rated moderate: meta-analysis methodology is strong, but the brief abstract lacks detail on which trials, total sample size, and duration of normoglycemia.

When this study was published

Published in 2024. Tirzepatide is a recently approved drug, so normoglycemia data is still emerging from clinical trials.

The bigger picture

Most diabetes drugs aim for HbA1c below 7%. Reaching 5.7% means blood sugar looks like someone without diabetes. If tirzepatide can reliably produce normoglycemia, it shifts the treatment goal from management to potential remission.

Questions still open

Does normoglycemia persist after stopping tirzepatide?
Is this true disease remission or just pharmacological suppression?
Which patient characteristics predict who will reach normoglycemia?

Common questions

Can tirzepatide cure diabetes?

It can bring blood sugar to normal levels during treatment, but whether this persists after stopping the drug remains unknown.

What does normoglycemia mean?

HbA1c below 5.7%, which is the same range as someone without diabetes. Most diabetes treatments aim for below 7%, so this is a much higher bar.

Read the original research

Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: A step closer to drug-induced diabetes remission?

Journal of diabetes and its complications, 38(8), 108800

View on PubMed ↗Publisher’s paper ↗

Citation

Popovic, Djordje S; Patoulias, Dimitrios; Koufakis, Theocharis; Stavropoulos, Konstantinos; Karakasis, Paschalis; Ruža, Ieva; Papanas, Nikolaos; Rizzo, Manfredi; Doumas, Michael. (2024). Achievement of normoglycemia with tirzepatide in type 2 diabetes mellitus: A step closer to drug-induced diabetes remission?. Journal of diabetes and its complications, 38(8), 108800. https://doi.org/10.1016/j.jdiacomp.2024.108800